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Abstract
 
Considerable research has focused on pain and other symptoms in terminal cancer patients 
referred to hospices and palliative care services. These patients differ from Dutch cancer 
patients in the palliative stage of their disease because the latter are cared for by general 
practitioners at home and medical specialists in outpatient departments. To clarify the 
experience of these Dutch patients, a study was started to investigate the prevalence and 
severity of pain and other symptoms as well as the functional status of consecutive patients 
visiting oncology outpatient departments for follow-up. After randomization, one group (I) of 
patients was interviewed at home by a general practitioner using structured questionnaires. 
The other group (II) received the questionnaires by mail, and scored the symptoms 
independently. The results of the symptom assessment show that patients in groups I and II 
 
suffered 2.4 (SD 
 
5
 
 1.7) and 2.8 (SD 
 
5
 
 2.0) symptoms, respectively. Between 30% and 40% 
of all patients reported constipation, nausea, loss of appetite, coughing, and dyspnea. These 
percentages were 50% lower when only moderate, severe, or extremely distressing symptoms 
were included. Sixty percent of all patients had pain, and 20% indicated a daytime pain 
score of 5 or greater on a scale of 0 to 10. Functional status was measured by the COOP-
WONCA charts; the mean score for the charts “physical ﬁtness” and “daily activities” was 1.5 
points lower for cancer patients than a random sample from the community of the same age 
and gender. The ﬁndings of this study should motivate doctors to put more energy in symptom 
assessment and interventions in palliative care. 
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Introduction
 
Palliative care for cancer patients is defined
as the active total care of patients at a time
when their disease is no longer responsive to
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curative treatment.
 
1
 
 It is known from several
studies that, in the palliative stage, cancer pa-
tients suffer from pain and other symptoms
that decrease the quality of life.
 
2–5
 
 The majority
of these studies describe the symptoms of a se-
lected group of patients who were referred be-
cause of their symptoms to a tertiary institution
such as a hospice
 
6
 
 or a special palliative care
service.
 
7
 
 This group does not represent the pa-
tients with disseminated cancer who are cared
for by general practitioners and medical spe-
cialists in the Netherlands. The latter patients
often are not considered terminal and there-
fore still visit outpatient departments for fol-
low-up.
The purpose of this cross-sectional study was
to investigate the prevalence and severity of
symptoms and functional status among outpa-
tients with disseminated cancer in the region of
the Comprehensive Cancer Center North Neth-
erlands. In addition, we investigated whether
patients score differently when they are inter-
viewed in their home by a general practitioner
or when they respond to mailed question-
naires. The same questionnaires also were sent
to a control group of noncancer patients ran-
domly selected from the community. This pro-
cedure allowed us to compare the scores for
cancer patients with those for a comparable
community-based population.
 
Methods
 
Study Subjects
 
Cancer patients participating in this study
had to fulfill the following eligibility criteria:
histologically proven malignancy, curative ther-
apy no longer feasible, life expectancy of more
than 1 month, not admitted to a hospital or a
nursing home, signed informed consent, and
age of 18 years or more.
Consecutive patients were asked by their
medical specialists to enter the study when they
visited the outpatient departments for follow-
up. The outpatient departments of radiother-
apy, medical oncology, gastroenterology, and
urology participated, and it was stressed that
consecutive patients had to enter the study and
that the presence or absence of a complaint or
symptom was neither an inclusion nor an ex-
clusion criterion.
After the patients consented, they were ran-
domly divided into two groups: Group I pa-
tients were assessed by means of a questionnaire
at home by a general practitioner researcher
and Group II patients received self-adminis-
tered questionnaires via the mail. The inter-
view and the mailing took place at least 2 weeks
after the outpatient follow-up visit.
Group III consisted of a sample of noncan-
cer patients of the same age randomly selected
from an urban and a rural family practice in
the same region. This sample is representative
for the community because, in the Nether-
lands, practically all inhabitants are registered
in general practices. Assuming a 50% re-
sponse, 140 controls received by mail the same
self-administered questionnaires as patients of
Group II.
 
Methods of Assessment
 
The symptoms of the cancer patients in both
groups and the control patients were assessed
using the Symptom Distress Scale
 
8
 
 and a nu-
merical pain rating scale.
 
9
 
 In addition, func-
tional status was scored with the help of the
COOP-WONCA charts. For scoring the ques-
tionnaires, the frame of reference was always
“the last 2 weeks.”
The symptom distress scale was originally de-
veloped and internationally tested by Mc-
Corkle et al.
 
10–12
 
 We have excluded the psycho-
social dimensions of the scale and added the
symptoms pruritis, dyspnea, urinary inconti-
nence, and hiccups to the original symptoms
of loss of appetite, nausea, vomiting, constipa-
tion, coughing. Each symptom is measured by
means of a 5-point scale: not at all 
 
5
 
 1, a lit-
tle 
 
5
 
 2, moderate 
 
5
 
 3, severe 
 
5
 
 4, and ex-
tremely distressing 
 
5
 
 5.
The pain questionnaire is based on numeri-
cal rating scales from 0 to 10. Patients have to
choose the number which most closely repre-
sents the severity of their pain: 0 is absence of
pain and 10 is pain as severe as can be imag-
ined. Pain at the moment of the interview,
mean pain during the day, and mean pain at
night were scored separately. Because pain can
also be noncancer-related, patients were asked
if they related their pain to cancer or to an-
other disease.
Measurement of functional status by the
COOP-WONCA charts is propagated by the
World Organization of General Practitio-
ners.
 
13,14
 
 The instrument consists of seven
charts to assess physical fitness, feelings, daily 
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activities, social activities, change in health,
overall health, and pain. Each chart consists of
a title, an illustration, and an ordinal 5-point
response scale ranging from none to maxi-
mum limitation. For the ‘change in health’
question the scale ranges from improvement
to deterioration. In the manual describing the
COOP-WONCA charts,
 
15
 
 a change of one
point is considered a moderate and 2 points a
considerable change.
 
Analysis
 
The statistical calculations were performed
using the SPSS-system. The mean pain scores
(
 
6
 
SD) were tabulated for the three groups.
The mean values include the score 0. In addi-
tion, the percentage of patients with daytime
pain and their corresponding scores were sepa-
rately tabulated.
The difference among Groups I, II and III in
percentages of patients suffering symptoms of
grade 2 and more, the mean pain scores and
the mean COOP-WONCA scores were tested
by one-way analysis of variance (ANOVA), with
post-hoc comparisons of Group I versus group
II and Group I and II versus Group III as ap-
propriate.
For Groups I and II, the Pearson correlation
coefficients among the scores of the symptom
distress scale, the pain scores, and the scores of
the COOP-WONCA charts also were calcu-
lated. Correlations were considered significant
at a 
 
P
 
 value less than 0.05.
 
Results
 
The recruitment of patients took place dur-
ing a period of 21 months. The written in-
formed consent procedure was a barrier for
about 20% of the patients who otherwise ful-
filled the inclusion criteria. A total of 187 pa-
tients consented to participate in the study and
were randomized to group I (
 
N
 
 
 
5
 
 91) and
group II (
 
N
 
 
 
5
 
 96). In group I, 11 patients re-
fused after initial consent, and four died. In
group II, five patients refused after initial con-
sent, four died, and 12 patients did not return
their questionnaire for unknown reasons. This
resulted in a total of 151 evaluable cancer pa-
tients. In group III, 77 of 140 controls (55%)
who received a questionnaire by mail re-
sponded. Patients’ characteristics, which were
well balanced between group I and II, are de-
scribed in Table 1.
Figure 1 shows that the cancer patients suf-
fered multiple symptoms, apart from pain. In
group I, 10.5% and in group II, 16% of the pa-
tients did not suffer any of the nine symptoms
of the symptom distress scale, and in group III,
40% of the controls were free of symptoms.
The majority of the cancer patients experi-
enced between one and five symptoms. Table
2, which shows the mean number of symptoms
per person in all three groups, indicates a sig-
nificant difference between the cancer patients
(groups I and II) and the controls (group III).
Moreover, Table 2 describes the percentage of
patients suffering a specific symptom, as well as
the differences among the groups based on the
severity of these symptoms.
With respect to pain, a total of 44 patients
(58%) of group I and 53 patients (71%) of
group II reported pain at one of the three in-
tervals assessed. When these 97 patients were
asked about the cause of their pain, 59 (60%)
assumed direct tumor involvement and the re-
maining patients reported a variety of causes,
including muscle pain, joint pain, previous
chemotherapy, surgery, or radiation therapy,
and ischialgia. When patients in group III were
asked about the cause of their pain 65% (
 
N
 
 
 
5
 
25) mentioned joint and muscle pain; 25% (
 
N
 
 
 
5
 
Table 1
 
Patient Characteristics
 
Group I 
(
 
N
 
 5
 
 76)
Group II 
(
 
N
 
 5
 
 75)
Group III
(
 
N
 
 5
 
 77)
Male/female 38/38 38/37 32/45
Mean age (
 
6
 
 SD) 61 
 
6
 
 11 60 
 
6
 
 14 50 
 
6
 
 10
Cancer site
Breast 25 28
Prostate 10 14
Lung 13 17
Gastro-intest. 11 8
Gynecological 3 5
Others 18 14
Metastases
Skeletal 40 45
Liver 14 13
Lymph nodes 15 10
Lung 10 7
Soft Tissue 3 2
Brain 2 3
Previous anti-cancer
treatment
Surgery 47 44
Radiotherapy 58 54
Chemotherapy 22 22 
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10) could not indicate the cause of their pain.
A total of 40 patients (51%) from group III
also reported pain according to the rating
scale at one of the three relevant times.
Table 3 describes the mean pain scores. Be-
cause these mean pain scores also include pa-
tients without pain, the percentages for all pa-
tients and controls, and their corresponding
values for daytime pain, are presented in Fig-
ure 2. This figure shows that 20% of the cancer
patients and 18% of the controls scored pain as
5 or higher during the day.
Functional status, measured as the mean
score per COOP-WONCA chart among cancer
patients compared to the control group, dif-
fered in some charts and almost none in oth-
ers. Differences between the two groups of can-
cer patients could not be found. The scores are
described in Table 4.
 
Correlations
 
For patients in both group I and II, the re-
sults of some COOP-WONCA charts correlated
significantly with some symptom scores, indi-
cating that the impairment of the patient’s
functional status was associated with symptom
distress (Table 5). Some of these significant cor-
Fig 1. Percentage patients with the corresponding number of symptoms determined by means of the symptom dis-
tress scale.
 
Table 2
 
Mean Number of Symptoms per Patient and Percentage Patients of Groups I, II or III 
Suffering a Sympton with Severity Grade 2 and Grade 3 or More Measured by Means of the 
Sympton Distress Scale
 
Group I (
 
N
 
 
 
5
 
 76) Group II(
 
N
 
 
 
5
 
 75) Group III (
 
N
 
 
 
5
 
 77)
Mean number of symptoms 
per patient (
 
6
 
 SD) 2.4 
 
6
 
 1.7 2.8 
 
6
 
 2.0 1.4* 
 
6
 
 1.6
Symptoms
 
$
 
 grade 2
 
 $
 
 grade 3
 
$
 
 grade 2
 
$
 
 grade 3
 
$
 
 grade 2
 
$
 
 grade 3
Constipation 39.5% 23.7% 41.3% 20.0% 18.2%* 3.9%
Nausea 38.2% 13.2% 45.3% 16.0% 16.9%* 2.6%
Loss of appetite 32.9% 17.1% 44.0% 22.7% 11.7%* 1.3%
Cough 32.9% 18.4% 34.7% 17.3% 22.1%* 9.1%
Vomiting 15.8% 2.6% 24.0% 1.3% 5.2%* 0.0%
Pruritis 27.6% 11.8% 26.7% 17.3% 18.2% 7.8%
Dyspnea 27.6% 15.8% 30.7% 13.3% 24.7% 6.5%
Urinary incontinence 15.8% 6.6% 28.0% 4.0% 14.3% 2.6%
Hiccups 11.8% 1.3% 8.0% 5.3% 9.1% 0.0%
 
No significant differences for contrast group I versus group II by one way ANOVA -test for symptoms 
 
$
 
 grade 2.
*
 
P
 
 < 0.05 for contrast groups I 
 
1
 
 II versus group III by one way ANOVA test for symptoms 
 
$
 
 grade 2. 
ANOVA, analysis of variance. 
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relations were between some COOP-WONCA
charts and the pain scales.
 
Discussion
 
This cross-sectional study shows that patients
with incurable cancer still visiting outpatient
departments suffer multiple symptoms, which
in most cases are mild. More than 60% re-
ported pain as their main symptom. For day-
time pain, 20% indicated the experience of se-
vere pain with a score of 5 and more on the
numerical rating scale. It is remarkable that in
the control group of patients without cancer,
18% reported pain of the same severity. The
correlation coefficients between the symptom
distress scale, pain scales and COOP-WONCA
charts showed that symptom distress and pain
can contribute to a decrease in the functional
status of cancer patients.
In the Netherlands, patients who do not
longer respond to anti-cancer treatment are pri-
marily cared for by their general practitioners
 
16
 
and will consult these practitioners in the case
of pain or other symptoms. These cancer pa-
tients also visit the oncology outpatient depart-
ments for psychological and follow-up reasons.
When the general practitioner is not able to
manage the pain and symptoms, the oncologist
who originally administered the anticancer
treatment is available for consultation. In addi-
tion, patients can be referred by their general
practitioner to university pain centers and an-
esthesiologists in regional hospitals.
The comparison of the results of this study
with those of other studies has its limitations
because different populations of cancer patients
and different kinds and numbers of symptoms
were investigated. Moreover, in our study, the pa-
tients were assessed only once. The percentage
patients suffering one or more specific symptoms
in our study is similar to the findings of Grond et
al.
 
17
 
 However, pain was an inclusion criterion in
the latter study, while in our study a random sam-
ple of incurable cancer patients with or without
complaints was investigated. In addition, Grond
et al. did not consider the severity of symptoms,
while we found a rather mild severity. This is
what one would expect for a group of patients
who are not necessarily terminal. Donnelly and
Walsh
 
18
 
 studied the symptoms of 1000 patients
with advanced cancer referred to a Palliative
Care Service. They found much higher percent-
ages for loss of appetite and dyspnea than our
patient group, most probably because then pa-
tients were in a more advanced stage of disease.
 
Table 3
 
Mean Pain Scores 
 
6
 
 SD According to the Three 
Numerical Rating Scales (0–10) for Groups I, II, 
and III
 
Group I
(
 
N
 
 
 
5
 
 76)
Group II
(
 
N
 
 
 
5
 
 75)
Group III
(
 
N
 
 
 
5
 
 77)
Pain at the interview 1.3 
 
6
 
 2.1 2.2* 
 
6
 
 2.4 1.5 
 
6
 
 2.4
Daytime pain 2.1 
 
6
 
 2.4 2.6 
 
6
 
 2.4 1.8 
 
6
 
 2.5
Pain at night 0.8 
 
6
 
 1.9 1.6 
 
6
 
 2.3 1.2 
 
6
 
 2.2
 
*
 
P
 
 < 0.05 for contrast group I versus group II by the one-way
ANOVA test.
Fig 2. Percentage patients of group I, group II and group III with a given average daytime pain as assessed by
means of the pain questionnaire. 
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Pain was prevalent in 68% of our patients
and thus a greater cause of concern than the
other symptoms. The finding that 61% of pa-
tients assume direct tumor involvement as the
cause of their pain is similar to the findings of
Foley,
 
3
 
 who noted that 62% of pain problems
in an outpatient population were attributed to
direct tumor involvement. Ventafridda et al.
 
19
 
described pain in 59% of 115 patients, Donnelly
and Walsh
 
18
 
 reported pain in 62% of 1000 pa-
tients, and Curtis et al.
 
20
 
 noted pain in 89% of
500 patients referred to a palliative care service.
The inclusion criteria for all of these studies dif-
fered from ours; specifically, patients in these
studies were referred because of symptoms.
In our study, 20% of patients reported a
pain score of five or more during the day. In
the course of personal contacts, we had the im-
pression that such a score represents substan-
tial pain, having a negative impact on daily life.
This corresponds with the opinion of Cleeland
et al.
 
21
 
 who believed outpatients with meta-
static cancer suffered substantial pain when
they scored pain as 5 or higher.
It is remarkable that the pain scores for the
cancer patients did not differ from the pain
scores of the control group, suggesting that
pain is a common symptom in this age group
and is frequently caused by noncancerous dis-
orders. Meyboom de Jong
 
22
 
 described morbid-
ity patterns of elderly patients in 12 Dutch gen-
eral practices and concluded that pain, and
especially pain of the musculosceletal system,
was the most frequent reason for encounter in
general practice. In this context, Twycross
stated that it is important to realize when deal-
ing with cancer patients that “when pain is
wrongly assumed to be cancerous in origin, it
tends to be invested with all of the negative im-
plications of cancer pain, which makes the
pain worse.”
 
23
 
The observed decline in functional status
compared to the response of a control group
indicated by the COOP-WONCA charts ‘physi-
cal fitness’ and ‘daily activities’ is understand-
able in view of the illness of our patients. In
fact, it is surprising that the chart “feelings”
does not yield a difference in response, be-
 
Table 4
 
Mean Score 
 
6
 
 SD per COOP-WONCA Chart (1-5)
 
COOP-WONCA charts
Group I
(
 
N
 
 5
 
 76)
Group II
(
 
N
 
 5
 
 75)
Group III
(
 
N
 
 5
 
 77)
Physical fitness 3.8 
 
6
 
 0.7 3.4 
 
6
 
 1.7 2.2* 
 
6
 
 1.0
Feelings 1.9 
 
6
 
 1.0 1.9 
 
6
 
 1.0 1.9 
 
6
 
 1.1
Daily activities 2.9 
 
6
 
 1.4 2.8 
 
6
 
 1.4 1.8* 
 
6
 
 1.0
Social activities 1.9 
 
6
 
 1.1 2.1 
 
6
 
 1.5 1.5* 
 
6
 
 0.8
Overall health 3.1 
 
6
 
 0.9 3.3 
 
6
 
 1.5 2.5* 
 
6
 
 1.0
Change in health 2.8 
 
6 
 
0.9 2.6 
 
6
 
 1.0 2.8 
 
6 0.5
Pain 2.2 6 1.2 2.4 6 1.1 2.0* 6 1.0
*P < 0.05 for contrast groups I 1 II versus group III by one-way ANOVA test.
Table 5
Spearman Correlation Coefficients Between the Symptom Distress Scales, Pain Rating 
Scales and COOP-WONCA Charts
Group I 1 II
N 5 151
Physical
fitness Feelings
Daily 
activities
Social 
activities
General 
health
Change 
in health Pain
Appetite 0.19 0.15 0.34 0.38 0.27 — 0.30
Nausea — — 0.35 0.25 0.34 — 0.34
Vomit — — 0.28 — — — 0.30
Constipation — 0.25 0.26 0.37 0.25 — 0.32
Cough — — — — 0.19 — —
Urinary incontinence — 0.23 — — 0.23 — —
Dyspnea — — 0.20 — 0.27 — —
Pain at the interview — 0.21 0.33 0.24 0.36 — 0.65
Daytime pain 0.16 0.31 0.37 0.36 0.40 0.23 0.78
Pain at night — 0.32 0.23 0.31 0.29 0.22 0.57
All correlation coefficients are significant at P < 0.05.296 Schuit et al. Vol. 16 No. 5 November 1998
cause one would expect more emotional prob-
lems in patients with disseminated cancer. This
lack of difference might be explained by our
personal impression that the patients were
somehow inhibited in expressing negative feel-
ings to protect their partners who were usually
present during the completion of the question-
naires. The score for the charts ‘overall health’
and ‘change in health’ was often scored a 3
(5good), indicating that denial of illness and
symptoms can occur. The treating doctor
should be aware of this.
No significant difference in outcome could
be found for the Symptom Distress Scale, the
pain scale, and the COOP-WONCA charts be-
tween group I and group II. Only the mean
score for pain at the interview differed between
these groups. This indicates that our question-
naires can be completed by cancer patients in-
dependently and that the presence of an inter-
viewer does not influence the answers.
Finally, the results of this study suggest that
better symptom recognition can be achieved if
symptoms are assessed actively by the attending
doctors, because patients frequently do not re-
port symptoms spontaneously.24 One of the
most important reasons for not reporting
symptoms is the fear of opioids, including the
fear of addiction and side effects. Thus, doc-
tors play an important role in patient educa-
tion on the treatment of pain and symptoms.25
This education must start early in the course of
the cancer because pain can already exist in an
early phase, as illustrated by this study.
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